Discovered some 50 years ago, aldosterone (ALDO) has come to be recognised as a mineralocorticoid hormone with well-known endocrine properties in epithelial cells that contribute to the pathophysiology of congestive heart failure. This includes Na + resorption at the expense of K + excretion in classic target tissues: kidneys, colon, sweat and salivary glands. Though less well known, Mg 2+ excretion is likewise enhanced by ALDO, while adrenal ALDO secretion is regulated by extracellular Mg 2+ ([Mg 2+ ] o ). An emerging body of information has and continues to identify other endocrine actions of ALDO receptor-ligand binding. They include: promoting an efflux of cytosolic free Mg 2+ , or [Mg 2+ ] i , in exchange for Na + in such non-epithelial cells as peripheral blood mononuclear cells; its influence on endothelial cell function; and its central actions that involve regulation of cerebrospinal fluid composition produced by epithelial cells of the choroid plexus, activity of the hypothalamic paraventricular nucleus involved in Na + appetite, Na + and H 2 O excretion and sympathetic nerve activity, and the regulation of TNF-α production from central and/or peripheral sources. Extra-adrenal steroidogenesis and auto/paracrine properties of ALDO generated de novo in the cardiovasculature are now under investigation and preliminary findings suggest they contribute to tissue repair. The past decade has witnessed a revival of interest in this steroid molecule. In years to come, an even broader understanding of ALDO's contribution to the pathophysiology of congestive heart failure will undoubtedly emerge.
Introduction
Aldosterone (ALDO) was discovered some 50 years ago. 1, 2 Termed electrocortin, identification of its 18-aldehyde steroid structure and adrenal origin led to its being renamed aldosterone (ALDO). ALDO's ability to alter Na + uptake in exchange for K + prompted Selye to refer to it as a mineralocorticoid. 3 During a decade of discovery that followed its identification, sites of ALDO's action and receptor-ligand binding were found to reside within epithelial cells of the kidney, colon, sweat and salivary glands. 4, 5 The importance of this circulating hormone in promoting salt and water retention at each of these target tissues was demonstrated in such oedema-forming states as congestive heart failure (CHF). Also confirmatory of its importance in CHF was the efficacy of spironolactone, an ALDO receptor antagonist introduced into clinical practice 45 years ago, in counteracting Na + retention and alleviating oedema. [4] [5] [6] [7] [8] A recent resurgence of interest in this steroid molecule in CHF has been driven by several observations. 9 In brief, this included: a recognition of ALDO's broader range of actions that extended beyond classic target tissues and which were associated with an adverse structural remodelling of the cardiovasculature that contributes to pathophysiologic expressions and progressive nature of CHF; 10 the inability of angiotensin-converting enzyme (ACE) inhibition to provide for sustained suppression of plasma ALDO in patients with CHF, 11, 12 which indicated that the regulation of its secretion by zona glomerulosa cells of the adrenal cortex is more complex than that governed by angiotensin II (Ang II) alone; and finally, the results of a controlled clinical trial (Randomised ALdactone Evaluation Study [RALES] ), conducted in 19 countries on five continents in over 1,600 patients with CHF, wherein spironolactone (vis-àvis placebo), in combination with an ACE inhibitor (ACE-I) and loop diuretic, reduced the risk of allcause and cardiac-related mortality and cardiovascular morbidity by 30%. 13 Herein, less well recognised properties of ALDO, mediated by receptor-ligand binding, are briefly reviewed. Each has the potential to contribute to the pathophysiology of CHF. They include its influence on: Mg 2+ balance and the role of extracellular Mg 2+ [Mg 2+ ] o in regulating adrenal ALDO secretion; vascular remodelling and immune cell activation; endothelial cell function; and the central nervous system. Finally, extraadrenal steroidogenesis of ALDO by the cardiovasculature is briefly considered. The interested reader is referred elsewhere 14 for a discussion of non-genomic, non-receptor-mediated actions of ALDO.
Aldosterone and Mg 2+ balance
The distribution of Mg 2+ within body tissues is as follows: 53% in bone, 27% in skeletal muscle and 19% in other soft tissues, such as the heart; less than 1% of total body Mg 2+ is present in blood; and cytosolic free Mg 2+ [Mg 2+ ] i , represents but 0.5-5% of total cellular Mg 2+ , with the remaining 80% bound to ATP and other phosphometabolites sequestered within such organelles as mitochondria Heart failure and the renin-angiotensinaldosterone system Weber 
Epithelial cells
In 1955, Mader and Iseri 16 reported that their patient with adrenal adenoma had experienced spontaneous episodes of hypomagnesaemia, together with enhanced Mg 2+ excretion in urine and stool. Others [17] [18] [19] [20] [21] [22] [23] [24] would also note the presence of hypomagnesaemia in patients with primary aldosteronism (PAL), suggesting Mg 2+ deficiency accompanies long-standing, ALDO-induced Mg 2+ excretion.These clinical findings implicated ALDO in regulating both K + and Mg 2+ excretion in classic target tissues. Horton and Biglieri 25 addressed urinary K + and Mg 2+ excretion in five patients with PAL, each of whom had low normal or reduced serum Mg 2+ levels, and reported their findings in 1962. The influence of surgical resection of adrenal adenoma on urinary K + and Mg 2+ excretion was assessed in two patients ( Figure 1 ). In both, there was an immediate and marked fall in excretion of these mono-and divalent cations after surgery, together with a gradual normalisation of plasma Mg 2+ . A lower basal excretion of Mg 2+ , comparable to values seen for normal controls on the same Mg 2+ diet, was seen post-operatively. In a third patient, spironolactone was shown to reduce both urinary K + and Mg 2+ excretion, both of which returned to previous increased basal levels following spironolactone discontinuation ( Figure 2 ). Thus, the importance of ALDO in promoting urinary Mg 2+ excretion was evident. Conn, who had coined the term PAL in 1954 to connote autonomous adrenal ALDO production independent of plasma renin activity, reviewed his personal series of 18 cases of PAL in 1963. Together with another 127 that had been reported in the literature,
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HEART FAILURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM he concluded that hypomagnesaemia, together with hypokalaemia, hypernatraemia, hypochloraemia and metabolic alkalosis, were the cardinal metabolic abnormalities of PAL. 26 The importance of the adrenal cortex in regulating Mg 2+ and K + excretion was further underscored in the setting of adrenal insufficiency or adrenalectomy. [27] [28] [29] [30] [31] ALDO treatment of dogs or rats with surgically-induced bilateral adrenalectomy was shown to increase faecal K + and Mg 2+ excretion and to normalise their plasma concentrations. 32, 33 Horton and Biglieri 25 treated an adrenalectomised patient with d-ALDO for eight days ( Figure 3 ); on day five of this regimen, spironolactone co-treatment was initiated. Exogenous ALDO promoted a prompt elevation in urinary K + and Mg + excretion that was abrogated by the ALDOreceptor antagonist. Thus, the body of evidence is compelling that ALDO promotes both K + and Mg 2+ excretion at classic target tissue sites.
Mg 2+ excretion is likely to be increased in patients with CHF, in whom elevated plasma ALDO levels are expected. In patients with CHF treated with a loop diuretic, there exists an independent stimulus to urinary Mg 2+ excretion and the potential for exaggerated Mg 2+ loss. 34, 35 Detection of biologically active, cytosolic free [Mg 2+ ] i (vis-à-vis its concentration in serum, which does not reflect intracellular Mg 2+ ) hinders the detection and assessment of this important clinical problem. Intracellular Mg 2+ deficiency may contribute to morbid and mortal events, such as sudden cardiac death, that occurs in 50% of patients with CHF. 36 The 30% reduction in risk of sudden cardiac death observed in the RALES trial may, in part, be related to spironolactone's ability to restore and preserve Mg 2+ homeostasis.
Non-epithelial cells ALDO regulates Mg 2+ exchange by non-epithelial cells, such as peripheral blood mononuclear cells (PBMC)
. ALDO binds to a single class of cytosolic receptors in these cells. 37 In patients with either PAL or renin-dependent, secondary aldosteronism (SAL),ALDO binding sites are reduced by 50%; following surgical removal of adenomatous adrenal tissue, receptor binding in PBMC is normalised. 38, 39 ALDO promotes the efflux of Mg 2+ from cultured human lymphocytes in exchange for Na + via receptor-ligand binding. This response, measured by a fluorescent probe (Mag-fura-2), is dependent on extracellular Na + and involves both transcription and protein synthesis, as demonstrated by its respective abrogation by cycloheximide and actinomycin D. 40 Lymphocyte ionised [Mg 2+ ] i is reduced in patients with PAL secondary to either adrenal adenoma or hyperplasia. 40 In uninephrectomised rats treated with ALDO by implanted minipump, we found PBMC [Mg 2+ ] i to be significantly reduced 41 and accompanied by immune cell activation. 42, 43 Mg 2+ and aldosterone secretion Extracellular Mg 2+ ([Mg 2+ ] o ) participates in the regulation of adrenal ALDO secretion to create a pathway of reciprocal regulation in Mg 2+ homeostasis ( Figure 4 ). In healthy, normotensive men and women, an intravenous infusion of MgSO 4 of several hours' duration will suppress plasma ALDO levels. 44, 45 Dietary-induced Mg 2+ deficiency with reduced [Mg 2+ ] o , on the other hand, is accompanied by an expanded width to the adrenal zona glomerulosa, together with hyperplasia of the renal juxtaglomerulosa cell, increased adrenal ALDO secretion, increased plasma ALDO and a reduction in urinary Na + /K + ratio. 46 51 The SAL that accompanies dietary Mg 2+ deficiency is associated with a time-dependent rise in [Na + ] i and [Ca 2+ ] i in heart, skeletal muscle, kidney and bone, which is suggestive of an inhibition of Na, K ATPase, a Mg 2+ -dependent pump, and increased Na + /Ca 2+ exchange at these sites. [52] [53] [54] Vascular remodelling and immune cell activation A structural remodelling of the cardiovasculature by fibrous tissue accompanies aldosteronism derived from either endogenous or exogenous sources. [55] [56] [57] [58] [59] [60] [61] [62] [63] This fibrogenic phenotype includes intramural arteries of the heart, kidney, pancreas, mesentery and vasa vasorum of aorta and pulmonary artery. Co-treatment with a receptor antagonist (e.g., spironolactone, eplerenone), in either non-depressor or depressor doses, prevents this remodelling, indicating its independence of elevations in blood pressure (BP). 58, [61] [62] [63] [64] [65] [66] [67] [68] [69] In a substudy to the RALES trial, survival benefit was associated with a reduction in circulating markers of collagen synthesis that presumably reflected an attenuation in ongoing vascular fibrosis. 70 In this connection, urinary excretion of hydroxyproline, a marker of collagen turnover, is increased in adrenalectomised rats treated with ALDO, 1% dietary NaCl, and cortisone. 70 Glucocorticoids, on the other hand, are known to reduce urinary hydroxyproline excretion and their inhibition of collagen formation in bone is associated with osteoporosis. 71 Campbell et al. 60 and Nicoletti and coworkers 61 each found that the perivascular fibrosis of the coronary vasculature that ultimately appears in aldosteronism is preceded by a proinflammatory vascular phenotype that features invading monocytes/macrophages and lymphocytes and adhesion molecule expression. These findings, including their independence of BP, were more recently confirmed by others. 63, 68, 69 An interrogation of molecular responses involved in the invasion of coronary vessels by these inflammatory cells were recently addressed in animal models of PAL and SAL. 62, 72 In rats receiving ALDO/salt treatment (ALDOST), where plasma renin and Ang II are each suppressed, Sun et al. 72 tested the hypothesis that oxidative stress was involved in the appearance of the pro-inflammatory/fibrogenic cardiac phenotype. At week 3 of ALDOST, there was no evidence of cardiac pathology; at weeks 4 and 5, however, inflammatory cells (monocytes/macrophages and lymphocytes) were found to have invaded intramural coronary vessels in both ventricles. Using immunohistochemistry, invading PBMC were found to express the gp91 phox subunit of NADPH oxidase, whose activation is a major source of superoxide in leukocytes, and 3nitrotyrosine, a product of peroxynitrite with stable protein tyrosine residues and where perox-ynitrite is formed by the reaction between superoxide and nitric oxide (NO). The RelA subunit of NFκB, a redox-sensitive transcription factor integral to inflammatory responses, was likewise activated in these cells. In situ hybridisation localised increased mRNA expression of intercellular adhesion molecule (ICAM)-1, monocyte chemoattractant protein (MCP)-1, and a pro-inflammatory cytokine tumour necrosis factor (TNF)-α at vascular sites that involved the normotensive, nonhypertrophied right atrium and ventricle and left atrium, as well as the hypertensive, hypertrophied left ventricle. Co-treatment with either spironolactone or an antioxidant (either pyrrolidine dithiocarbamate or N-acetylcysteine) prevented the appearance of these cells and associated molecular responses, as well as the subsequent perivascular fibrosis. Thus, ALDOST induces oxi/nitrosative stress within inflammatory cells invading the intramural coronary vasculature and it is this pro-inflammatory vascular phenotype that leads to intramural coronary artery pathology and the subsequent perivascular fibrosis. Why should this be the case? Did this only occur at vascular sites or was there a prior activation of PMBC?
We recently identified an ALDO-mediated reduction in [Mg 2+ ] i that appears in PBMC at week 1 of ALDOST, 43 long before the appearance of cardiac pathology at week 4. The early activation of these cells is evident in their transcriptome (expressed genes) and proteome (expressed proteins). 42, 43 The interrogation of complex molecular events that account for immune cell activation and subsequent homing of these cells to the heart, may explain why cardiac pathology does not appear until week 4 of ALDOST and calls into question the prospect of an autoimmune response, not unlike that which can follow myocardial infarction (MI). 73 In rodents treated with a Mg 2+ -deficient diet, a putative state of exaggerated aldosteronism (see above), lymphocyte Mg 2+ is reduced to an extent comparable to the Mg 2+ depletion that appears in skeletal muscle and cardiac tissue. 74 Weglicki and co-workers have identified an early (week 1) induction of oxi/nitrosative stress and depletion of antioxidant defences in PBMC and endothelial cells. [75] [76] [77] [78] The lymphocyte activation featured here includes their production of proinflammatory cytokines and a neurogenic peptide, substance P, together with the expression of its receptors. 79 Cardiac lesions first appear in this model during week 3 and can be prevented by a substance P receptor antagonist. 79 The potential for the SAL that accompanies human CHF to likewise be accompanied by immune cell activation remains unexplored. Nonetheless, the prospect exists that the now recognised 'cytokine storm' of CHF, which features elevations in such circulating proinflammatory cytokines as TNF-α and IL-6, has an immune cell origin. Cells of the monocyte-phagocyte system are a potent source of these cytokines. An alternative source of cytokine production in heart failure is the central nervous system. 80 Irrespective of their origin, prolonged elevations in these proinflammatory cytokines contribute to the progressive systemic illness that accompanies CHF and which features tissue wasting to eventuate in cardiac cachexia. 81
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Endothelial cell dysfunction
In patients with PAL or renal artery stenosis with SAL, forearm vasomotor reactivity to endothelial cell-dependent acetylcholine is diminished compared with normotensive controls, while nonendothelial cell-dependent sodium nitroprussideinduced vasodilatation is preserved. 82 Four weeks after surgical removal of adrenal adenoma, the impairment in endothelial cell-dependent vasodilation is restored. In the SAL that accompanies CHF, Farquharson and Struthers 83 found diminished forearm vasomotor reactivity to acetylcholine to be normalised after one month of spironolactone treatment. Acetylcholine-induced, NO-dependent vasorelaxation of aortic rings is reduced in rats following MI. 84 This vasomotor dysfunction, together with increased superoxide formation by aortic tissue, is normalised by spironolactone, either alone or in combination with an ACE-I. 84 In cultured aortic endothelial cells, reduced Mg 2+ concentration of culture medium is associated with increased oxidant production and reduced intracellular glutathione, an antioxidant reserve consumed in neutralising oxi/nitrosative stress. 75 Abnormal Mg 2+ homeostasis could represent the underlying pathophysiological basis for endothelial dysfunction seen in either PAL or SAL.
Central actions of aldosterone
Additional sites of action of ALDO that fall outside of its classic target tissues include the central nervous system, where ALDO receptors are found at diverse sites, including epithelial cells of the choroid plexus. In this connection, a role for ALDO in the genesis of idiopathic intracranial hypertension (IIH) has been proposed, given the reported association between IIH with PAL and SAL 85, 86 and the prevalence of headache among patients with PAL. 26 That this proposition does not apply to all patients with IIH is underscored by its appearance in patients with adrenal insufficiency, unless ALDO would be produced in situ within the central nervous system 87 as is now recognised to be the case for the cardiovasculature. 88, 89 The choroid plexus, a site of high-affinity ALDO receptor binding, is involved in the production of cerebrospinal fluid (CSF) and is a target site for ALDO, spironolactone and ouabain, an endogenous digitalis-like substance released by the adrenals and the hypothalamic-pituitary axis. [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] ALDO exerts its biologic actions on epithelial cells by enhancing the activity and number of Na, K ATPase pumps in their apical membrane. A ouabain-sensitive Na, K ATPase is present in the microvilli of the plexus and is involved in the regulation of CSF formation and electrolyte composition (e.g., ouabain reduces CSF production). ALDO is present in CSF, where its concentration correlates with plasma levels. Either the systemic or intracerebroventricular administration of a mineralocorticoid (ALDO or DOC) is accompanied by a fall in CSF [K + ], together with a rise in arterial pressure, without changes in blood volume, cardiac output, plasma catecholamines or vasopressin. 99, 100 This hypertensive response is abrogated by intracerebroventricular infusion of K + or a mineralocorticoid receptor antagonist. 99, 101 ALDO, therefore, has a central action involved in the regulation of BP, as well as CSF volume and composition. Produced locally within the brain, ALDO's paracrine properties may likewise contribute to BP regulation. 87 Research by Felder et al. [102] [103] [104] has broadened the perspective of ALDO's central actions, which may contribute to the pathophysiology of CHF. The hypothalamic paraventricular nucleus (PVN), a forebrain site involved in the regulation of extracellular volume and sympathetic nerve activity, is governed by circulating neurohormones and by effector signals originating from the brainstem. In rats with MI induced by coronary artery ligation, the activity of the PVN is increased. Systemic or intracerebroventricular administration of spironolactone reduces this activity, improves baroreflex regulation of renal sympathetic nerve activity (albeit in a time-dependent manner) and prevents the increase in Na + appetite and decline in urinary Na + and H 2 O excretion that appear in this model. 102, 103 Plasma levels of TNF-α rise progressively over weeks 1-3 following MI, a response abrogated by intracerebroventricular infusion of spironolactone started 24 hours after coronary ligation, suggesting that central ALDO receptor activation is involved in regulating the release of this pro-inflammatory cytokine. 104 The cellular source of TNF-α, however, remains uncertain and may include central and/or peripheral tissues.
Extra-adrenal aldosterone production and tissue repair
Some 40 years ago, Lockett et al. [105] [106] [107] [108] [109] [110] reported that the beating heart and contracting soleus muscle of cats were sites of steroid generation; the substance resembled 18-D-aldosterone.They found this molecule in coronary venous blood and demonstrated its ability to promote renal salt and water retention. These findings lay fallow until the past decade, when Takeda 111, 112 identified the mRNA expression of ALDO synthase (CYP11B2) and ALDO production in rodent vascular tissue. Silvestre and coworkers 113 likewise demonstrated the expression of this enzyme, integral to the biosynthesis of ALDO, in rodent heart, where ALDO generation was regulated by Ang II, a low Na + or high K + diet, or adrenocorticotropin (ACTH). Subsequently, the expression of this enzyme was identified in human cardiovascular tissue, where it was localised to vascular smooth muscle and endothelial cells. 112, 114 Even more recently, and in contrast to normal human hearts, ALDO production was reported to be increased in the failing human left ventricle, based on coronary sinus levels of ALDO that exceed those found in 115 There exists an upregulated expression of CYP11B2 in the left ventricle of the failing human heart of diverse aetiological origins. 116 Additionally, 11β-hydroxysteroid dehydrogenase, an enzyme critical to maintaining the specificity of the mineralocorticoid receptor, given its equal affinity for mineralo-and glucocorticoids, has been found in human cardiac tissue. 117 Following MI in rodents, macrophages and myofibroblasts involved in tissue repair express renin,ACE and Ang II receptors, predominantly of the AT 1 -subtype. [118] [119] [120] [121] [122] This has implicated locallyproduced Ang II at sites of injury in regulating collagen turnover, which has been further suggested by the cardioprotective actions of losartan, an AT 1receptor antagonist, in attenuating fibrous tissue formation at, and remote to, the site MI. 123 Locallyproduced Ang II is also involved in regulating de novo ALDO production in the infarcted heart, 124 which likewise may contribute to tissue repair. Increased expression of ALDO synthase and ALDO tissue levels, together with increased concentrations of Ang II, have been observed in non-infarcted rat myocardium following coronary artery ligation. 124, 125 Treatment with losartan prevented these responses related to de novo ALDO production. Either losartan or spironolactone treatment prevented the accompanying accumulation of collagen at sites remote to the MI, suggesting the involvement of Ang II-driven local ALDO production in regulating tissue repair. Hayashi et al. 126 have reported that ALDO is extracted by the heart following MI, and the transcardiac ALDO gradient (between aorta and coronary sinus) is correlated with coronary venous effluent levels of a serological marker of collagen turnover (procollagen type III aminoterminal peptide, PIIINP) that has been associated with LV dilatation and poor function and prognosis. ALDO is extracted by the chronically failing human heart of diverse aetiological origins, a response blocked by spironolactone. 127 Under circumstances in which circulating ALDO is not increased, spironolactone attenuates neointimal thickening following vascular barotrauma, 128 tissue repair at sites of fibrous tissue formation 129 and vascular injury in stroke-prone rats. 130 These observations further suggest that auto/paracrine properties of locally-produced ALDO participate in tissue repair.
Future directions
Since its discovery some 50 years ago, ALDO has well-established importance in clinical medicine, including its role in CHF. The past decade has witnessed a resurgence of interest in this the adrenal's most potent mineralocorticoid, as has its de novo production through steroidogenesis within the cardiovasculature and brain. An everexpanding role for this steroid molecule in the metabolism of mono-and divalent cations by epithelial and non-epithelial cells has warranted an even broader perspective of its portfolio of actions. The many peripheral and central actions of ALDO that can contribute to the pathophysiology of the CHF syndrome remain to be defined. This is no more evident than in the adverse structural remodelling of the heart and systemic organs that accompanies chronic elevations in plasma ALDO (inappropriate relative to dietary Na + ) and which may be secondary to PBMC activation induced by [Mg 2+ ] i depletion and transduced by oxi/nitrosative stress. Molecular mechanisms involved in immune cell responses remain to be elucidated. Today's technologies will permit an assessment of ALDO's role in altering the molecular phenotype of these immune cells, specifically their transcriptome and proteome. Such insights may provide for the development of serologic biomarkers that address the risk, onset and progression of vascular injury in CHF and could lead the way toward refined and even newer drug targets. 
